(Reuters) - Merck & Co Inc (N:MRK) reported a 7.6% fall in second-quarter sales on Friday as a drop in visits to doctors' offices because of the COVID-19 pandemic hurt sales of several important drugs.
Sales fell to $10.87 billion from $11.76 billion a year earlier.
Net income attributable to shareholders rose to $3 billion, or $1.18 per share, in the quarter, from $2.67 billion, or $1.03 per share, a year earlier.